Validation of SCORE2 on a sample from the Russian population and adaptation for the very high cardiovascular disease risk region

被引:1
|
作者
Svinin, Gleb E. [1 ,2 ]
Kutsenko, Vladimir A. [1 ,2 ]
Shalnova, Svetlana A. [1 ]
Yarovaya, Elena B. [1 ,2 ]
Imaeva, Asiia E. [1 ]
Balanova, Yulia A. [1 ]
Kapustina, Anna V. [1 ]
Muromtseva, Galina A. [1 ]
Drapkina, Oxana M. [3 ]
机构
[1] Natl Med Res Ctr Therapy & Prevent Med, Dept Epidemiol Noncommunicable Dis, Moscow, Russia
[2] Lomonosov Moscow State Univ, Fac Mech & Math, Dept Probabil Theory, Moscow, Russia
[3] Natl Med Res Ctr Therapy & Prevent Med, Moscow, Russia
来源
PLOS ONE | 2024年 / 19卷 / 04期
关键词
D O I
10.1371/journal.pone.0300974
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
SCORE2 (Systematic COronary Risk Evaluation 2) is a risk assessment scale for cardiovascular events, presented in 2021 by the European Society of Cardiology. Both for training and validation of the SCORE2 model, representative samples from the Russian population were not used. Therefore, we aimed to validate SCORE2 on a such sample. For this purpose, we used a sample from the ESSE-RF epidemiological study consisting of 7251 participants aged 40-69 years without history of CVDs. We performed the validation by comparing SCORE2 risk estimates for ESSE-RF participants with the observed incidence of cardiovascular events in the study, adjusted for event information losses. The validation demonstrated that SCORE2 risk estimates were accurate for Russian men and inaccurate for Russian women. Together with the quantitative assessment of risk, SCORE2 offers its interpretation in terms of 10-year CVD risk group: low-moderate, high, and very high. For Russian men we considered the original interpretation of the SCORE2 estimates to be questionable because almost none of the men would be categorized as having "low-to-moderate" 10-year CVD risk. This problem would be typical for all countries of the very high CVD risk region. Therefore, we proposed a new interpretation of the SCORE2 risk estimates for men from the very high risk region. According to the proposed interpretation, the fraction of men in ESSE-RF in "low-to-moderate" 10-year CVD risk increased from 2% to 18% and the fraction of men in "very high" CVD risk decreased from 63% to 20% as compared to the original interpretation. The proposed interpretation would allow a more personalized approach to CVD treatment and optimize the burden on primary healthcare in the very high risk region countries.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Comparison of SCORE and SCORE2 in determination rates with very high cardiovascular risks
    Demirci, D.
    Demirci, D. Ersan
    Gerald, C.
    Guven, A. Z.
    Elhan, A. H.
    Gibson, C. M.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [2] SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: an external validation study
    Kist, Janet M.
    Vos, Rimke C.
    Mairuhu, Albert T. A.
    Struijs, Jeroen N.
    van Peet, Petra G.
    Vos, Hedwig M. M.
    van Os, Hendrikus J. A.
    Beishuizen, Edith D.
    Sijpkens, Yvo W. J.
    Faiq, Mohammad A.
    Numans, Mattijs E.
    Groenwold, Rolf H. H.
    ECLINICALMEDICINE, 2023, 57
  • [3] How the new ESC cardiovascular risk chart, SCORE2, identifies additional high risk patients in a population free of cardiovascular disease with large waist circumference
    Douhard, Sarah
    Snel, Marc
    Van Gaal, Luc
    Brohet, Christian
    Scheen, Andre
    Demeure, Fabian
    Descamps, Olivier S.
    ACTA CLINICA BELGICA, 2022, 77 : 24 - 25
  • [4] Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohort
    van Apeldoorn, Joshua A. N.
    Hageman, Steven H. J.
    Harskamp, Ralf E.
    Agyemang, Charles
    van den Born, Bert-Jan H.
    van Dalen, Jan Willem
    Galenkamp, Henrike
    Hoevenaar-Blom, Marieke P.
    Richard, Edo
    van Valkengoed, Irene G. M.
    Visseren, Frank L. J.
    Dorresteijn, Jannick A. N.
    van Charante, Eric P. Moll
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 417
  • [5] Validation of the SCORE2 risk prediction algorithm in a Portuguese population: A new model to estimate 10-year cardiovascular disease incidence in Europe
    Temtem, Margarida
    Mendonca, Maria Isabel
    Santos, Marina
    Sa, Debora
    Sousa, Francisco
    Freitas, Sonia
    Borges, Sofia
    Henriques, Eva
    Rodrigues, Mariana
    Soares, Carolina
    Rodrigues, Ricardo
    Serrao, Marco
    Drumond, Antonio
    Sousa, Ana Celia
    Reis, Roberto Palma
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (08) : 437 - 444
  • [6] Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model
    Hageman, Steven H. J.
    Huang, Zijuan
    Lee, Hokyou
    Kaptoge, Stephen
    Dorresteijn, Jannick A. N.
    Pennells, Lisa
    Di Angelantonio, Emanuele
    Visseren, Frank L. J.
    Kim, Hyeon Chang
    Johar, Sofian
    EUROPEAN HEART JOURNAL, 2024,
  • [7] Score2: A New Updated Algorithm to Predict Cardiovascular Disease Risk in Europe
    Chipayo-Gonzales, David
    Ramakrishna, Harish
    Nunez-Gil, Ivan J.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (01) : 18 - 21
  • [8] Cardiovascular risk assessment with SCORE, SCORE2 and D:A:D in people living with HIV with high prevalence of cardiovascular risk factors
    Miguel, M. J.
    Cruz, D.
    Albuquerque, A. A.
    Gomes, A.
    Pintassilgo, I.
    Marques, N.
    HIV MEDICINE, 2023, 24 : 283 - 283
  • [9] Estimation of 10-Year Cardiovascular Disease Risk in the Portuguese Population Using the Systematic Coronary Risk Evaluation 2 (SCORE2)
    Santos, Maria
    Sousa-uva, Mafalda
    Namorado, Sonia
    Goncalves, Teresa
    Matias Dias, Carlos
    Gaio, Vania
    ACTA MEDICA PORTUGUESA, 2024, 37 (10) : 720 - 724
  • [10] Adding ethnicity to cardiovascular risk prediction: external validation and model updating of SCORE2 using data from the multiethnic HELIUS population cohort
    Van Apeldoorn, J. A. N.
    Hageman, S. H. J.
    Harskamp, R. E.
    Agyemang, C.
    van den Born, B. J. H.
    Van Dalen, J. W.
    Galenkamp, H.
    Richard, E.
    Valkengoed, I. G. M.
    Visseren, F. L. J.
    Dorresteijn, J. A. N.
    Van Charante, E. P. Moll
    EUROPEAN HEART JOURNAL, 2024, 45